Free newsletter for those with myelodysplastic syndromes (MDS)

The Leukemia & Lymphoma Society (LLS) has a new newsletter for people living with myelodysplastic syndromes (MDS). MDS today contains news about advances in the diagnosis and treatment of these diseases. The first issue, Spring 2010, features leading expert in the field, Stephen D. Nimer, M.D., Memorial Sloane-Kettering Cancer Center in New York.

Plus, two free teleconferences will be available in the next month as well.
yelodysplastic Syndromes (MDS):
An Update on Diagnosis and Treatment

This program will feature Stephen D. Nimer, MD, Chief, Hematology Service, Vice Chairman for Faculty Development, Department of Medicine, Alfred P. Sloan Chair, Memorial Sloan-Kettering Cancer Center, Professor of Medicine and Pharmacology at Weill Cornell Medical College in New York, NY.

Participants will have the opportunity to ask the presenter questions during the program.

This program is sponsored by The Leukemia & Lymphoma Society and is supported by a grant from Celgene Corporation.

5/20/10
1-2:30 PM ET

(877) 804-2063

Stem Cell Transplantation: Dialogue with the Experts

This program will feature Corey S. Cutler, MD, Assistant Professor of Medicine, Harvard Medical School, Division of Hematological Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA and Willis H. Navarro, MD, Medical Director, Transplant Services, National Marrow Donor Program, Minneapolis, MN.

Participants will have the opportunity to ask the presenters questions during the program.

This program is supported by The Leukemia & Lymphoma Society in collaboration with the National Marrow Donor Program.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap